Humanized anti-ACTH antibodies and use thereof

A method for treating a subject with a condition associated with increased ACTH, cortisol, aldosterone, or corticosterone levels, wherein said subject comprises elevated ACTH, cortisol, aldosterone, and/or corticosterone levels, by administering an effective amount of an anti-ACTH antibody or antibody fragment comprising the heavy chain CDR1, CDR2, and CDR3 polypeptides of SEQ ID NO:

• 564;
• SEQ ID NO:
• 566;
• and SEQ ID NO:
• 568, and the light chain CDR1, CDR2, and CDR3 polypeptides of SEQ ID NO:
• 584;
• SEQ ID NO:
• 586;
• and SEQ ID NO:
• 588, wherein said anti-ACTH antibody or antibody fragment reduces said elevated ACTH, cortisol, aldosterone, and/or corticosterone levels.

A method for treating a condition associated with elevated ACTH, cortisol, aldosterone, and/or corticosterone in a subject in need thereof, wherein said subject comprises elevated ACTH, cortisol, aldosterone, and/or corticosterone levels, comprising administering to the subject in need thereof an anti-human adrenocorticotrophic hormone (ACTH) antibody or antibody fragment, which comprises the heavy chain CDR1, CDR2, and CDR3 polypeptides of SEQ ID NO:

• 564;
• SEQ ID NO:
• 566;
• and SEQ ID NO:
• 568, and the light chain CDR1, CDR2, and CDR3 polypeptides of SEQ ID NO:
• 584;
• SEQ ID NO:
• 586;
• and SEQ ID NO:
• 588, wherein the condition is selected from the group consisting of:
• congenital adrenal hyperplasia (CAH), Classical CAH, Nonclassical CAH, familial glucocorticoid deficiency (FGD), ACTH-driven hypercortisolism, acute coronary syndrome, acute heart failure, atherosclerosis, atrial fibrillation, cachexia, cancer, Cushing's Syndrome resulting from ectopic ACTH expression, Cushing's Syndrome resulting from ectopic ACTH expression associated with small cell lung cancer, Cushing's Syndrome resulting from ectopic ACTH expression associated with non-small cell lung cancer (NSCLC), Cushing's Syndrome resulting from ectopic ACTH expression associated with pancreatic carcinoma, Cushing's Syndrome resulting from ectopic ACTH expression associated with neural tumors, Cushing's Syndrome resulting from ectopic ACTH expression associated with thymoma, cardiac conditions, cardiac fibrosis, cardiovascular disorders, chronic renal failure, chronic stress syndrome, cognitive dysfunction, Alzheimer's disease, congestive heart failure, Conn's syndrome, coronary heart diseases, Cushing's Disease, Cushing's Syndrome, depression, anxiety disorders, diabetes, endothelial dysfunction, exercise intolerance, familial hyperaldosteronism, fibrosis, galactorrhea, heart failure, hyperaldosteronism, hypercortisolemia, hypertension, hyperinsulinemia, hypokalemia, impaired cardiac function, increased formation of collagen, inflammation, metabolic syndrome, muscle atrophy, conditions associated with muscle atrophy, myocardiac fibrosis, nephropathy, obesity, post-myocardial infarction, primary hyperaldosteronism, remodeling following hypertension, renal failure, restenosis, secondary hyperaldosteronism, sleep apnea, sleep disorders, stress related conditions, and syndrome X, or comprising Allgrove syndrome, bilateral adrenalectomy, or Nelson's syndrome, wherein said subject is a human, and wherein said anti-ACTH antibody or antibody fragment reduces one or more of cortisol, aldosterone, and corticosterone levels in the treated subject.